In a move that should please industry, the US FDA intends to substantially reduce the amount of human drug and biosimilar user fees that it carries over from year to year by the end of fiscal year 2022.
However, FDA's targeted reduction of $159.2m in carryover balances over the next five years could leave the agency with less...








